Announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist.

Ajinomoto announces Phase 2a outcomes of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients Ajinomoto Pharmaceuticals Co., Ltd best online pharmacy . announced on May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in individuals with ulcerative colitis were offered in the Joint Presidential Plenary Program at Digestive Disease Week 2014 held May 3 – 6 in Chicago, IL, USA. In inflammatory bowel disease including ulcerative colitis, extreme infiltration of lymphocytes into the inflamed lesion may be linked to the disease progression. AJM300 includes a new mode of action that stops the adhesion and invasion of lymphocytes generally to the inflamed lesion.